Neither Neoadjuvant nor Adjuvant Therapy Increases Survival After Biliary Tract Cancer Resection with Wide Negative Margins

Journal of Gastrointestinal Surgery

Volumn 16, Issue 9, 2012, Pages 1666-1671

  Glazer, Evan S ^a,b   Liu, Ping ^a   Abdalla, Eddie K ^a   Vauthey, Jean Nicolas ^a   Curley, Steven A ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Rice University   (United States)

Author keywords

Adjuvant; Cholangiocarcinoma; Neoadjuvant; Resection

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; FEMALE; GALLBLADDER TUMOR; HUMAN; INTRAHEPATIC BILE DUCT; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84865510514     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1935-1     Document Type: Article

References (12)

1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273-1281.
2. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer. 2009; 101(4): 621-627.
3. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007; 96(6): 896-902.
4. Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009; 73(1): 148-153.
5. Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg. 2007; 11(11): 1488-1496; discussion 1496-1487.
6. Murakami Y, Uemura K, Hayasidani Y, Sudo T, Hashimoto Y, Ohge H, Sueda T. Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci. 2009; 54(6): 1360-1364.
7. Eckel F, Jelic S. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4: 46-48.
8. Wolpin BM, Mayer RJ. A step forward in the treatment of advanced biliary tract cancer. N Engl J Med. 2010; 362(14): 1335-1337.
9. Seehofer D, Thelen A, Neumann UP, Veltzke-Schlieker W, Denecke T, Kamphues C, Pratschke J, Jonas S, Neuhaus P. Extended bile duct resection and [corrected] liver and transplantation in patients with hilar cholangiocarcinoma: long-term results. Liver Transpl. 2009; 15(11): 1499-1507.
10. Hernandez J, Cowgill SM, Al-Saadi S, Villadolid D, Ross S, Kraemer E, Shapiro M, Mullinax J, Cooper J, Goldin S, Zervos E, Rosemurgy A. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol. 2008; 15(3): 807-814.
11. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, Sueda T. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol. 2007; 95(3): 207-212.
12. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95(8): 1685-1695.